Alivus Life Sciences Limited
NSE: ALIVUSMarket Closed • NSE
Day range
52 week range
Alivus Life Sciences Limited closed at INR1309.50 (-2.41%) on volume 0.31x its 20-day average, trading 12.34% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -1.6% QoQ
2026-09-01
DIVIDEND Announced
Dividend - Rs 5 Per Share
2025-09-01
DIVIDEND Announced
Dividend - Rs 5 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
High Cash Flow Conversion: CFO/PAT averaged 1x over last 3 years
Risks
Elevated Leverage Burden: Debt-to-Equity stands at 1.70x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 01 Sept 2026 | Dividend | ₹5.00 / share | — | 01 Sept 2026 |
| 01 Sept 2025 | Dividend | ₹5.00 / share | — | 01 Sept 2025 |
| 17 Oct 2023 | Dividend | ₹22.50 / share | — | 17 Oct 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 22 Sept 2023 |
| 24 Mar 2023 | Dividend | ₹21.00 / share | — | 24 Mar 2023 |
| — | Dividend | ₹10.50 / share | — | 15 Sept 2022 |
| 23 Nov 2021 | Dividend | ₹10.50 / share | — | 22 Nov 2021 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
IndiaHealthcare
Is Alivus Life Sciences Limited Shariah compliant?
Alivus Life Sciences Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.35%) complies with AAOIFI threshold (≤ 33%).
What is Alivus Life Sciences Limited's current valuation relative to peers?
Alivus Life Sciences Limited trades at a P/E of 26.7x compared to the sector median of 37x, and a Price-to-Book of 4.8x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 1.70x. Interest coverage is 134.4x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 1.3% while net profit growth averaged 3.1%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.